Cord blood stem cells: A review of potential neurological applications

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

It is estimated that as many as 128M individuals in the United States, or 1 in 3 people, might benefit from regenerative medicine therapy. Many of these usages include applications that affect the nervous system, including cerebral palsy, stroke, spinal cord injury and neurodegenerative disease such as Parkinson's. The numbers of such individuals affected range from 10,000 (for cerebral palsy) to 700,000 annually (for stroke) at a cost of more than $65B. For the foreseeable future, regenerative medicine entrée to the clinic will depend upon the development of adult or non-embryonic stem (ES) cell therapies. Currently, non-ES cells easily available in large numbers from affected individuals can be found in the bone marrow, adipose tissue and umbilical cord blood (CB). It is our belief that CB stem cells are the best alternative to ES cells as these stem cells can be used to derive tissues from the mesodermal, endodermal and ectodermal germ lineages. CB contains a mixture of different types of stem cells in numbers not seen in any other location including embryonic-like stem cells, hematopoietic stem cells, endothelial stem cells, epithelial stem cells, mesenchymal stem cells and unrestricted somatic stem cells. This review will summarize the findings reported in the literature with regards to the use of CB stem cells to neurological applications including in vitro work, pre-clinical animal studies, and patient clinical trials.

Original languageEnglish (US)
Pages (from-to)269-274
Number of pages6
JournalStem Cell Reviews
Volume4
Issue number4
DOIs
StatePublished - Dec 2008

Fingerprint

Fetal Blood
Blood Cells
Stem Cells
Regenerative Medicine
Cerebral Palsy
Embryonic Stem Cells
Stroke
Adult Stem Cells
Spinal Cord Diseases
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Mesenchymal Stromal Cells
Spinal Cord Injuries
Neurodegenerative Diseases
Nervous System
Adipose Tissue
Endothelial Cells
Cell Count
Bone Marrow
Epithelial Cells

Keywords

  • Cerebral palsy
  • Cord blood
  • Neurological
  • Stem cells
  • Stroke

ASJC Scopus subject areas

  • Developmental Biology
  • Cancer Research

Cite this

Cord blood stem cells : A review of potential neurological applications. / Harris, David T.

In: Stem Cell Reviews, Vol. 4, No. 4, 12.2008, p. 269-274.

Research output: Contribution to journalArticle

@article{f33779f22e1b493f8b1bb8ae6e7dbc67,
title = "Cord blood stem cells: A review of potential neurological applications",
abstract = "It is estimated that as many as 128M individuals in the United States, or 1 in 3 people, might benefit from regenerative medicine therapy. Many of these usages include applications that affect the nervous system, including cerebral palsy, stroke, spinal cord injury and neurodegenerative disease such as Parkinson's. The numbers of such individuals affected range from 10,000 (for cerebral palsy) to 700,000 annually (for stroke) at a cost of more than $65B. For the foreseeable future, regenerative medicine entr{\'e}e to the clinic will depend upon the development of adult or non-embryonic stem (ES) cell therapies. Currently, non-ES cells easily available in large numbers from affected individuals can be found in the bone marrow, adipose tissue and umbilical cord blood (CB). It is our belief that CB stem cells are the best alternative to ES cells as these stem cells can be used to derive tissues from the mesodermal, endodermal and ectodermal germ lineages. CB contains a mixture of different types of stem cells in numbers not seen in any other location including embryonic-like stem cells, hematopoietic stem cells, endothelial stem cells, epithelial stem cells, mesenchymal stem cells and unrestricted somatic stem cells. This review will summarize the findings reported in the literature with regards to the use of CB stem cells to neurological applications including in vitro work, pre-clinical animal studies, and patient clinical trials.",
keywords = "Cerebral palsy, Cord blood, Neurological, Stem cells, Stroke",
author = "Harris, {David T.}",
year = "2008",
month = "12",
doi = "10.1007/s12015-008-9039-8",
language = "English (US)",
volume = "4",
pages = "269--274",
journal = "Stem Cell Reviews and Reports",
issn = "1550-8943",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Cord blood stem cells

T2 - A review of potential neurological applications

AU - Harris, David T.

PY - 2008/12

Y1 - 2008/12

N2 - It is estimated that as many as 128M individuals in the United States, or 1 in 3 people, might benefit from regenerative medicine therapy. Many of these usages include applications that affect the nervous system, including cerebral palsy, stroke, spinal cord injury and neurodegenerative disease such as Parkinson's. The numbers of such individuals affected range from 10,000 (for cerebral palsy) to 700,000 annually (for stroke) at a cost of more than $65B. For the foreseeable future, regenerative medicine entrée to the clinic will depend upon the development of adult or non-embryonic stem (ES) cell therapies. Currently, non-ES cells easily available in large numbers from affected individuals can be found in the bone marrow, adipose tissue and umbilical cord blood (CB). It is our belief that CB stem cells are the best alternative to ES cells as these stem cells can be used to derive tissues from the mesodermal, endodermal and ectodermal germ lineages. CB contains a mixture of different types of stem cells in numbers not seen in any other location including embryonic-like stem cells, hematopoietic stem cells, endothelial stem cells, epithelial stem cells, mesenchymal stem cells and unrestricted somatic stem cells. This review will summarize the findings reported in the literature with regards to the use of CB stem cells to neurological applications including in vitro work, pre-clinical animal studies, and patient clinical trials.

AB - It is estimated that as many as 128M individuals in the United States, or 1 in 3 people, might benefit from regenerative medicine therapy. Many of these usages include applications that affect the nervous system, including cerebral palsy, stroke, spinal cord injury and neurodegenerative disease such as Parkinson's. The numbers of such individuals affected range from 10,000 (for cerebral palsy) to 700,000 annually (for stroke) at a cost of more than $65B. For the foreseeable future, regenerative medicine entrée to the clinic will depend upon the development of adult or non-embryonic stem (ES) cell therapies. Currently, non-ES cells easily available in large numbers from affected individuals can be found in the bone marrow, adipose tissue and umbilical cord blood (CB). It is our belief that CB stem cells are the best alternative to ES cells as these stem cells can be used to derive tissues from the mesodermal, endodermal and ectodermal germ lineages. CB contains a mixture of different types of stem cells in numbers not seen in any other location including embryonic-like stem cells, hematopoietic stem cells, endothelial stem cells, epithelial stem cells, mesenchymal stem cells and unrestricted somatic stem cells. This review will summarize the findings reported in the literature with regards to the use of CB stem cells to neurological applications including in vitro work, pre-clinical animal studies, and patient clinical trials.

KW - Cerebral palsy

KW - Cord blood

KW - Neurological

KW - Stem cells

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=58149401451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149401451&partnerID=8YFLogxK

U2 - 10.1007/s12015-008-9039-8

DO - 10.1007/s12015-008-9039-8

M3 - Article

C2 - 18679834

AN - SCOPUS:58149401451

VL - 4

SP - 269

EP - 274

JO - Stem Cell Reviews and Reports

JF - Stem Cell Reviews and Reports

SN - 1550-8943

IS - 4

ER -